198 related articles for article (PubMed ID: 27566247)
21. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
22. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
[TBL] [Abstract][Full Text] [Related]
23. Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
Mitri ZI; Parmar S; Johnson B; Kolodzie A; Keck JM; Morris M; Guimaraes AR; Beckett BR; Borate U; Lopez CD; Kemmer KA; Alumkal JJ; Beer TM; Corless CL; Mills GB; Gray JW; Bergan RC
J Transl Med; 2018 Dec; 16(1):358. PubMed ID: 30551737
[TBL] [Abstract][Full Text] [Related]
24. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
[TBL] [Abstract][Full Text] [Related]
27. Institutional implementation of clinical tumor profiling on an unselected cancer population.
Sholl LM; Do K; Shivdasani P; Cerami E; Dubuc AM; Kuo FC; Garcia EP; Jia Y; Davineni P; Abo RP; Pugh TJ; van Hummelen P; Thorner AR; Ducar M; Berger AH; Nishino M; Janeway KA; Church A; Harris M; Ritterhouse LL; Campbell JD; Rojas-Rudilla V; Ligon AH; Ramkissoon S; Cleary JM; Matulonis U; Oxnard GR; Chao R; Tassell V; Christensen J; Hahn WC; Kantoff PW; Kwiatkowski DJ; Johnson BE; Meyerson M; Garraway LA; Shapiro GI; Rollins BJ; Lindeman NI; MacConaill LE
JCI Insight; 2016 Nov; 1(19):e87062. PubMed ID: 27882345
[No Abstract] [Full Text] [Related]
28. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project.
Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
[TBL] [Abstract][Full Text] [Related]
30. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
32. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
33. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
34. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.
Ikeda S; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cancer Biol Ther; 2019; 20(2):219-226. PubMed ID: 30339521
[TBL] [Abstract][Full Text] [Related]
36. Oncologist use and perception of large panel next-generation tumor sequencing.
Schram AM; Reales D; Galle J; Cambria R; Durany R; Feldman D; Sherman E; Rosenberg J; D'Andrea G; Baxi S; Janjigian Y; Tap W; Dickler M; Baselga J; Taylor BS; Chakravarty D; Gao J; Schultz N; Solit DB; Berger MF; Hyman DM
Ann Oncol; 2017 Sep; 28(9):2298-2304. PubMed ID: 28911072
[TBL] [Abstract][Full Text] [Related]
37. Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies.
Zimmer K; Kocher F; Spizzo G; Salem M; Gastl G; Seeber A
Comput Struct Biotechnol J; 2019; 17():447-453. PubMed ID: 31007870
[TBL] [Abstract][Full Text] [Related]
38. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
39. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
[TBL] [Abstract][Full Text] [Related]
40. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
